Literature DB >> 16025284

The ultrastructure of peripheral nerve, motor end-plate and skeletal muscle in patients suffering from spinal muscular atrophy with respiratory distress type 1 (SMARD1).

Alexander Diers1, Marcel Kaczinski, Katja Grohmann, Christoph Hübner, Gisela Stoltenburg-Didinger.   

Abstract

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is genetically and clinically distinct from classic spinal muscular atrophy (SMA1). It results from mutations in the gene encoding immunoglobulin mu-binding protein 2 (IGHMBP2) on chromosome 11q13. Patients develop distally pronounced muscular weakness and early involvement of the diaphragm, resulting in respiratory failure. Sensory and autonomic nerves are also affected at later stages of the disease. We investigated peripheral nerves, skeletal muscles and neuromuscular junctions (NMJ) ultrastructurally in five unrelated patients and three siblings with genetically confirmed SMARD1. In mixed motor and sensory nerves we detected Wallerian degeneration and axonal atrophy similar to the ultrastructural findings described in SMA1. Isolated axonal atrophy was evident in purely sensory nerves. All investigated NMJ of patients with SMARD1 were dysmorphic and lacked a terminal axon. Moreover, we also observed characteristics of neuropathies, such as abnormalities in myelination, that have not been described in spinal muscular atrophies so far. Based on these findings we conclude that impairment of IGHMBP2 function leads to axonal degeneration, abnormal myelin formation, and motor end-plate degeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16025284     DOI: 10.1007/s00401-005-1056-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  11 in total

1.  Dissection of the transversus abdominis muscle for whole-mount neuromuscular junction analysis.

Authors:  Lyndsay Murray; Thomas H Gillingwater; Rashmi Kothary
Journal:  J Vis Exp       Date:  2014-01-11       Impact factor: 1.355

2.  Selective vulnerability in neuronal populations in nmd/SMARD1 mice.

Authors:  Eric Villalón; Monir Shababi; Rachel Kline; Zachary C Lorson; Kyra M Florea; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

Review 3.  Unraveling the genetics of distal hereditary motor neuronopathies.

Authors:  Joy Irobi; Ines Dierick; Albena Jordanova; Kristl G Claeys; Peter De Jonghe; Vincent Timmerman
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 4.  Respiratory failure in infants due to spinal muscular atrophy with respiratory distress type 1.

Authors:  Alberto Giannini; Anna Maria Pinto; Giordano Rossetti; Edi Prandi; Danilo Tiziano; Christina Brahe; Nardo Nardocci
Journal:  Intensive Care Med       Date:  2006-09-09       Impact factor: 17.440

5.  Rescue of a Mouse Model of Spinal Muscular Atrophy With Respiratory Distress Type 1 by AAV9-IGHMBP2 Is Dose Dependent.

Authors:  Monir Shababi; Zhihua Feng; Eric Villalon; Christine M Sibigtroth; Erkan Y Osman; Madeline R Miller; Patricka A Williams-Simon; Abby Lombardi; Thalia H Sass; Arleigh K Atkinson; Michael L Garcia; Chien-Ping Ko; Christian L Lorson
Journal:  Mol Ther       Date:  2016-02-10       Impact factor: 11.454

6.  Muscle fiber-type selective propensity to pathology in the nmd mouse model of SMARD1.

Authors:  Eric Villalón; Naomi N Lee; Jose Marquez; Christian L Lorson
Journal:  Biochem Biophys Res Commun       Date:  2019-06-28       Impact factor: 3.575

7.  Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes.

Authors:  Wilfried Rossoll; Gary J Bassell
Journal:  Results Probl Cell Differ       Date:  2009

8.  Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2.

Authors:  Ellen Cottenie; Andrzej Kochanski; Albena Jordanova; Boglarka Bansagi; Magdalena Zimon; Alejandro Horga; Zane Jaunmuktane; Paola Saveri; Vedrana Milic Rasic; Jonathan Baets; Marina Bartsakoulia; Rafal Ploski; Pawel Teterycz; Milos Nikolic; Ros Quinlivan; Matilde Laura; Mary G Sweeney; Franco Taroni; Michael P Lunn; Isabella Moroni; Michael Gonzalez; Michael G Hanna; Conceicao Bettencourt; Elodie Chabrol; Andre Franke; Katja von Au; Markus Schilhabel; Dagmara Kabzińska; Irena Hausmanowa-Petrusewicz; Sebastian Brandner; Siew Choo Lim; Haiwei Song; Byung-Ok Choi; Rita Horvath; Ki-Wha Chung; Stephan Zuchner; Davide Pareyson; Matthew Harms; Mary M Reilly; Henry Houlden
Journal:  Am J Hum Genet       Date:  2014-10-30       Impact factor: 11.025

9.  The Ighmbp2D564N mouse model is the first SMARD1 model to demonstrate respiratory defects.

Authors:  Caley E Smith; Monique A Lorson; Sara M Ricardez Hernandez; Zayd Al Rawi; Jiude Mao; Jose Marquez; Eric Villalón; Amy N Keilholz; Catherine L Smith; Mona O Garro-Kacher; Toni Morcos; Daniel J Davis; Elizabeth C Bryda; Nicole L Nichols; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2022-04-22       Impact factor: 5.121

10.  Differentiation defects in primary motoneurons from a SMARD1 mouse model that are insensitive to treatment with low dose PEGylated IGF1.

Authors:  Frank Krieger; Friedrich Metzger; Sibylle Jablonka
Journal:  Rare Dis       Date:  2014-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.